Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2010

View Archived Issues

Synthesis and effects of EC-23 on human stem cells described

PF-3450074 inhibits HIV infection by destabilizing viral capsid

MK-0752 shows promise in patients with breast cancer

New antagonists of proteinase-activated PAR1 receptor identified

Abbott patents new activators of voltage-gated K(V)7 potassium channels

New inhibitors of focal adhesion kinase 1 claimed

Novartis divulges new neprilysin inhibitors

New activators of glycoprotein hormone FSH receptor discovered

Scientists unveil mechanism leading to resistance of HIV to maraviroc

[18F]-Marimastat-aryltrifluoroborate described as useful for PET imaging of breast cancer

Phase II study evaluates RGN-259 in dry eye syndrome

Centocor Ortho Biotech files sBLA for Remicade for pediatric ulcerative colitis

Antares files NDA for Anturol gel in overactive bladder

CEQ-508 receives FDA orphan drug status in familial adenomatous polyposis

Forest acquires Gruenenthal's cystic fibrosis franchise in Europe

Cel-Sci begins phase III trial of Multikine in head and neck cancer

Ziopharm Oncology treats first patient in phase I trial of palifosfamide

Recordati and Merck KGaA enter licensing agreement for Cardicor in Italy

Phase I/II trial of belinostat/Tarceva combination in NSCLC advances

Florida Hospital, Sanford-Burnham and Takeda partner to target obesity

Bristol-Myers Squibb and Otsuka to copromote Sprycel in Japan

Phase I/II data reported on OMS-201 in patients undergoing ureteroscopy

Advanced Cell Technology seeks European orphan drug status for MA-09-HRPE

New partial agonists of PPAR-gamma disclosed

Merrion and Novo Nordisk sign agreement for GIPET drug delivery technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...